CD4 and cancer: Because data from BTK-deficient or inhibitor-treated myeloid cells in the context of cancer are scarce, it is not clear whether BTK inhibition by e.g. ibrutinib is based on its specificity for BTK in particular myeloid cells and/or due to off-target effects in signaling pathways in CD4+ or CD8+ T cells.